Beyond Bone Cement: A New Implant Rebuilds Fractured Spines

THE HAGUE, NETHERLANDS – June 17, 2026

For the millions of people who suffer a vertebral compression fracture (VCF) each year, the diagnosis often heralds a future of chronic pain, stooped posture, and lost independence. For decades, the primary treatments have involved injecting bone cement to stabilize the fracture—a method akin to patching a crumbling wall. But today, Dutch medical technology company Amber Implants announced a significant step forward in a clinical trial that could shift the paradigm from patching to rebuilding.

The company is expanding its pivotal European EXPAND study for the VCFix® Spinal System, an innovative implant designed not just to fill a void, but to reconstruct the damaged vertebra from within. This advancement isn't just another incremental improvement; it represents a fundamental rethinking of how to treat a condition that affects an estimated 7.5 million new patients annually worldwide, many of whom are elderly and vulnerable.

Deconstructing a New Standard

To grasp the significance of VCFix®, one must first understand the limitations of the current standard of care. Procedures like vertebroplasty and kyphoplasty involve injecting a medical-grade cement, polymethyl methacrylate (PMMA), into the collapsed bone. While minimally invasive and effective at reducing pain for many, these techniques are not without serious drawbacks. The cement can leak into surrounding tissues, potentially causing nerve damage or traveling to the lungs. Furthermore, the newly rigid vertebra can create stress on adjacent spinal levels, leading to new fractures—a devastating domino effect.

Amber Implants aims to break this cycle by offering a solution centered on biomechanical restoration. The VCFix® system is a small, 3D-printed titanium alloy implant that is inserted into the fractured vertebra through a minimally invasive procedure. Its genius lies in its mechanism. Once in place, it expands craniocaudally (from top to bottom), exerting up to 1200 newtons of force to gently push the collapsed bone back to its original height. Crucially, it provides internal scaffolding and pedicle anchorage, supporting both the front and back columns of the spine—addressing a key weakness of cement-based procedures.

"The EXPAND study represents an important step in the maturation of our clinical program," stated Dr. Banafsheh Sajadi, Co-Founder and Chief Operating Officer of Amber Implants, in today's press release. "By evaluating VCFix® in a standalone configuration, with or without bone cement, EXPAND reflects an important evolution in vertebral reconstruction, focused not only on treating the fracture, but also supporting three-column spinal stability."

Perhaps its most compelling feature is its ability to function without bone cement. The implant’s perforated, 3D-printed structure is optimized to encourage the patient's own bone to grow into and through it, creating a durable, biological fusion over time. This cement-free option eliminates the risks associated with PMMA while promoting a more natural healing process. According to surgeons familiar with the technology, this represents a "remarkable innovation" in the field, with the potential to become a new standard of care.

A Tangible Hope for Millions

The need for such an innovation is staggering. Vertebral fractures are a silent epidemic; up to two-thirds of cases go undiagnosed, leaving patients to suffer in silence. The consequences are severe, leading to a cascade of health problems, from debilitating pain and reduced lung function to a marked increase in mortality. For this vast and often undertreated population, the results from Amber Implants' first-in-human study offer a tangible sense of hope.

In that initial trial involving patients with severe, disabling osteoporotic fractures, the outcomes were striking. One year after the procedure, no device-related adverse events were reported. Patients experienced immediate and sustained pain reduction, with pain scores dropping by more than 8 points on a 10-point scale. Functionality saw an even more dramatic improvement, with disability scores plummeting by 84 points on the Oswestry Disability Index. Patients were reportedly able to walk freely upon discharge from the hospital. These results, achieved with or without the use of cement, demonstrate a profound impact on quality of life.

Today's announcement that the EXPAND study is growing from its initial two clinical sites to eight centers across Germany and France is a critical step in validating these results across a broader, more diverse patient population. It signals a move from a promising concept to a robustly tested therapy.

"EXPAND represents the next critical step in validating a treatment philosophy centered on vertebral reconstruction rather than augmentation alone," said Dr. Mo Ahmadi, the company's Co-Founder and Chief Technology Officer. His statement underscores the core mission: to provide a more complete and targeted approach to spine care.

Charting a Path from Trial to Treatment

Bringing a disruptive medical device to market is a marathon, not a sprint, requiring a methodical journey through rigorous clinical validation and regulatory hurdles. Amber Implants appears to be navigating this path with strategic precision. The company has already achieved significant milestones, including receiving a coveted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2021.

More recently, in September 2025, the VCFix® system secured FDA 510(k) clearance for use with bone cement in the United States. This clearance not only provides a crucial entry point into the world's largest medical device market but also serves as a powerful validation of the device's fundamental safety and performance. The company is now planning a commercial pilot program in the U.S. for early 2026, even as it pursues a broader European CE Mark for standalone, cementless use.

The parallel advancement of clinical trials and commercial activities across two continents demonstrates a well-capitalized and confident strategy. By building a mountain of evidence, Amber Implants is not just aiming to win regulatory approval; it is seeking to convince a generation of surgeons to adopt a new philosophy of fracture repair. As the company continues to generate data from the EXPAND study, it reinforces the belief that VCFix® could be a transformative option for physicians and the millions of patients they treat.